These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 28502768)

  • 21. Liposomal formulations for treating lysosomal storage disorders.
    Tomsen-Melero J; Merlo-Mas J; Carreño A; Sala S; Córdoba A; Veciana J; González-Mira E; Ventosa N
    Adv Drug Deliv Rev; 2022 Nov; 190():114531. PubMed ID: 36089182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects.
    Herzeg A; Borges B; Lianoglou BR; Gonzalez-Velez J; Canepa E; Munar D; Young SP; Bali D; Gelb MH; Chakraborty P; Kishnani PS; Harmatz P; Cohen JL; MacKenzie TC
    Prenat Diagn; 2023 Dec; 43(13):1638-1649. PubMed ID: 37955580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.
    Placci M; Giannotti MI; Muro S
    Adv Drug Deliv Rev; 2023 Jun; 197():114683. PubMed ID: 36657645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.
    Pardridge WM
    Adv Drug Deliv Rev; 2022 May; 184():114234. PubMed ID: 35307484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment for Lysosomal Storage Disorders.
    Sheth J; Nair A
    Curr Pharm Des; 2020; 26(40):5110-5118. PubMed ID: 33059565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
    Ries M
    J Inherit Metab Dis; 2017 May; 40(3):343-356. PubMed ID: 28314976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
    Hsu J; Northrup L; Bhowmick T; Muro S
    Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
    Marques ARA; Di Spiezio A; Thießen N; Schmidt L; Grötzinger J; Lüllmann-Rauch R; Damme M; Storck SE; Pietrzik CU; Fogh J; Bär J; Mikhaylova M; Glatzel M; Bassal M; Bartsch U; Saftig P
    Autophagy; 2020 May; 16(5):811-825. PubMed ID: 31282275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.
    Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
    Meena NK; Raben N
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy.
    Baldo G; Giugliani R; Matte U
    Med Hypotheses; 2014 Apr; 82(4):478-80. PubMed ID: 24560457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
    Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
    Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision Medicine for Lysosomal Disorders.
    Pinto E Vairo F; Rojas Málaga D; Kubaski F; Fischinger Moura de Souza C; de Oliveira Poswar F; Baldo G; Giugliani R
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32722587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory watch: enhanced chance of success for protein replacement therapies.
    Crunkhorn S
    Nat Rev Drug Discov; 2013 Jun; 12(6):414. PubMed ID: 23722335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.